Pradimicin S, a highly soluble nonpeptidic small-size carbohydrate-binding antibiotic, is an anti-HIV drug lead for both microbicidal and systemic use

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 4, 2010, Pages 1425-1435

  Balzarini, Jan ^a   François, Katrien O ^a   Van Laethem, Kristel ^a   Hoorelbeke, Bart ^a   Renders, Marleen ^a   Auwerx, Joeri ^a   Liekens, Sandra ^a   Oki, Toshikazu ^b   Igarashi, Yasuhiro ^b   Schols, Dominique ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b TOYAMA PREFECTURAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CALCIUM ION; CD209 ANTIGEN; CHEMOKINE; CYTOKINE; GLYCAN DERIVATIVE; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; MANNOSE; PRADIMICIN A; PRADIMICIN S; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CANCER CELL CULTURE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG MECHANISM; GENOTYPE; GLYCOSYLATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; PHENOTYPE; PRIORITY JOURNAL; RAJI CELL; SIMIAN IMMUNODEFICIENCY VIRUS; SURFACE PLASMON RESONANCE; VIRUS CULTURE; VIRUS INFECTION; VIRUS INHIBITION; VIRUS ISOLATION; VIRUS STRAIN; VIRUS TRANSMISSION;

ANTHRACYCLINES; ANTI-BACTERIAL AGENTS; ANTI-HIV AGENTS; ANTI-INFECTIVE AGENTS; CACO-2 CELLS; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; CHEMOKINES; COCULTURE TECHNIQUES; CYTOKINES; DRUG RESISTANCE, VIRAL; DRUG STABILITY; HELA CELLS; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP41; HIV-1; HIV-2; HUMANS; MODELS, MOLECULAR; SIMIAN IMMUNODEFICIENCY VIRUS; SOLUBILITY; VIRUS INTERNALIZATION;

EID: 77950104390     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01347-09     Document Type: Article

References (33)

1. Auwerx, J., K. O. François, K. Covens, K. Van Laethem, and J. Balzarini. 2008. Glycan deletions in the HIV-1 gp120 V1/V2 domain compromise viral infectivity, sensitize the mutant virus strains to carbohydrate-binding agents and represent a specific target for therapeutic intervention. Virology 382:10-19.
2. Balzarini, J. 2006. Inhibition of HIV entry by carbohydrate-binding proteins. Antiviral Res. 71:237-247.
3. Balzarini, J., D. Schols, J. Neyts, E. Van Damme, W. Peumans, and E. De Clercq. 1991. Alpha-(1-3)- and alpha-(1-6)-D-mannose-specific plant lectins are markedly inhibitory to human immunodeficiency virus and cytomegalo-virus infections in vitro. Antimicrob. Agents Chemother. 35:410-416.
4. Balzarini, J., K. Van Laethem, S. Hatse, K. Vermeire, E. De Clercq, W. Peumans, E. Van Damme, A.-M. Vandamme, A. Bölmstedt, and D. Schols. 2004. Profile of resistance of human immunodeficiency virus to mannosespecific plant lectins. J. Virol. 78:10617-10627.
5. Balzarini, J., K. Van Laethem, S. Hatse, M. Froeyen, W. Peumans, E. Van Damme, and D. Schols. 2005. Carbohydrate-binding agents cause deletions of highly conserved glycosylation sites in HIV GP120: a new therapeutic concept to hit the achilles heel of HIV. J. Biol. Chem. 280:41005-41014.
6. Balzarini, J., K. Van Laethem, W. J. Peumans, E. J. Van Damme, A. Bolmstedt, F. Gago, and D. Schols. 2006. Mutational pathways, resistance profile, and side effects of cyanovirin relative to human immunodeficiency virus type 1 strains with N-glycan deletions in their gp120 envelopes. J. Virol. 80:8411-8421.
7. Balzarini, J., Y. Van Herrewege, K. Vermeire, G. Vanham, and D. Schols. 2007. Carbohydrate-binding agents efficiently prevent dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN)-directed HIV-1 transmission to T-lymphocytes. Mol. Pharmacol. 71:3-11.
8. Balzarini, J., K. Van Laethem, D. Daelemans, S. Hatse, A. Bugatti, M. Rusnati, Y. Igarashi, T. Oki, and D. Schols. 2007. Pradimicin A, a carbohydrate-binding nonpeptidic lead compound for treatment of infections with viruses with highly glycosylated envelopes, such as human immunodeficiency virus. J. Virol. 81:362-373.
9. Chang, T., and M. E. Klotman. 2004. Defensins: natural anti-HIV peptides. AIDS Res. 6:1161-1168.
10. de Jager, W., H. te Velthuis, B. J. Prakken, W. Kuis, and G. T. Rijkers. 2003. Simultaneous detection of 15 human cytokines in a single sample of stimulated peripheral blood mononuclear cells. Clin. Diagn. Lab. Immunol. 10:133-139.
11. de Witte, L., A. Nabatov, M. Pion, D. Fluitsma, M. A. de Jong, T. de Gruijl, V. Piguet, Y. van Kooyk, and T. B. Geijtenbeek. 2007. Langerin is a natural barrier to HIV-1 transmission by Langerhans cells. Nat. Med. 13:367-371.
12. Drickamer, K., and M. E. Taylor. 2006. Targeting diversity. Nat. Struct. Mol. Biol. 12:830-831.
13. Ezekowitz, R. A. 2003. Role of the mannose-binding lectin in innate immunity. J. Infect. Dis. 187(Suppl. 2):S335-S339.
14. Geijtenbeek, T. B., R. Torensma, S. J. van Vliet, G. C. van Duijnhoven, G. J. Adema, Y. van Kooyk, and C. G. Figdor. 2000. Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses. Cell 100:575-585.
15. Geijtenbeek, T. B., D. S. Kwon, R. Torensma, S. J. van Vliet, G. C. van Duijnhoven, J. Middel, I. L. Cornelissen, H. S. Nottet, V. N. KewalRamani, D. R. Littman, C. G. Figdor, and Y. van Kooyk. 2000. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 100:587-597.
16. Hoshino, H., J. Seki, and T. Takeuchi. 1989. New antifungal antibiotics, benanomicins A and B inhibit infection of T-cell with human immunodeficiency virus (HIV) and syncytium formation by HIV. J. Antibiot. (Tokyo) 42:344-346.
17. Hu, M., Y. Ishizuka, Y. Igarashi, T. Oki, and H. Nakanishi. 1999. NMR study of pradimicin derivative BMY-28864 and its interaction with calcium ions in D2O. Spectrochim. Acta A Mol. Biomol. Spectrosc. 55A:2547-2558.
18. Huskens, D., K. Van Laethem, K. Vermeire, J. Balzarini, and D. Schols. 2007. Resistance of HIV-1 to the broadly HIV-1-neutralizing, anti-carbohydrate antibody 2G12. Virology 360:294-304.
19. Huskens, D., K. Vermeire, E. Vandemeulebroucke, J. Balzarini, and D. Schols. 2008. Safety concerns for the potential use of cyanovirin-N as a microbicidal anti-HIV agent. Int. J. Biochem. Cell Biol. 40:2802-2814.
20. Kondo, S., S. Gomi, K. Uotani, S. Miyakawa, S. Inouye, D. Ikeda, and T. Takeuchi. 1992. New hydroxybenanomicins produced by Actinomadura. Drugs Exp. Clin. Res. 18:217-224.
21. Kwong, P. D., R. Wyatt, J. Robinson, R. W. Sweet, J. Sodroski, and W. A. Hendrickson. 1998. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393:648-659.
22. Leonard, C. K., M. W. Spellman, L. Riddle, R. J. Harris, J. N. Thomas, and T. J. Gregory. 1990. Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. J. Biol. Chem. 265:10373-10382.
23. Liu, Y., J. R. Carroll, L. A. Holt, J. McMahon, B. Giomarelli, and G. Ghirlanda. 2009. Multivalent interactions with gp120 are required for the anti-HIV activity of cyanovirin. Biopolymers 92:194-200.
24. Oki, T., M. Konishi, K. Tomatsu, K. Tomita, K. Saitoh, M. Tsunakawa, M. Nishio, T. Miyaki, and H. Kawaguchi. 1988. Pradimicin, a novel class of potent antifungal antibiotics. J. Antibiot. (Tokyo) 41:1701-1704.
25. Pollicita, M., D. Schols, S. Aquaro, W. J. Peumans, E. J. Van Damme, C. F. Perno, and J. Balzarini. 2008. Carbohydrate-binding agents (CBAs) inhibit HIV-1 infection in human primary monocyte-derived macrophages (MDMs) and efficiently prevent MDM-directed viral capture and subsequent transmission to CD4+ T lymphocytes. Virology 370:382-391.
26. Saitoh, K., O. Tenmyo, S. Yamamoto, T. Furumai, and T. Oki. 1993. Pradimicin S, a new pradimicin analog. I. Taxonomy, fermentation and biological activities. J. Antibiot. (Tokyo) 46:580-588.
27. Saitoh, K., T. Tsuno, M. Kakushima, M. Hatori, T. Furumai, and T. Oki. 1993. Pradimicin S, a new pradimicin analog. II. Isolation and structure elucidation. J. Antibiot. (Tokyo) 46:406-411.
28. Tanabe-Tochikura, A., T. S. Tochikura, O. Yoshida, T. Oki, and N. Yamamoto. 1990. Pradimicin A inhibition of human immunodeficiency virus: attenuation by mannan. Virology 176:467-473.
29. Ueki, T., K. Numata, Y. Sawada, M. Nishio, H. Ohkuma, and S. Toda. 1993. Studies on the mode of antifungal action of pradimicin antibiotics. II. Dmannopyranoside-binding site and calcium-binding site. J. Antibiot. (Tokyo) 46:455-464.
30. Ueki, T., M. Oka, Y. Fukagawa, and T. Oki. 1993. Studies on the mode of antifungal action of pradimicin antibiotics. III. Spectrophotometric sequence analysis of the ternary complex formation of BMY-28864 with D-mannopyranoside and calcium. J. Antibiot. (Tokyo) 46:465-477.
31. Van Damme, E., W. J. Peumans, A. Pusztai, and S. Bardocz. 1998. Handbook of plant lectins: properties and biomedical applications. John Wiley & Sons, Hoboken, NJ.
32. Van Kooyk, Y., and T. B. Geijtenbeek. 2003. DC-SIGN: escape mechanism for pathogens. Nat. Rev. Immunol. 3:697-709.
33. Van Laethem, K., Y. Schrooten, P. Lemey, E. Van Wijngaerden, S. De Wit, M. Van Ranst, and A.-M. Vandamme. 2005. A genotypic resistance assay for the detection of drug resistance in the human immunodeficiency virus type 1 envelope gene. J. Virol. Methods 123:25-34.